4D Molecular Therapeutics CEO David Kirn disposes of common shares worth $1,068,651.63PUBT·1 day ago, 03:07 PMFDMT-1.68%
4D Molecular Therapeutics (NASDAQ:FDMT) Trading Down 3.7% - Here's What HappenedMarket Beat·1 day ago, 03:00 PMFDMT-1.68%
4D Molecular Therapeutics posts corporate presentation highlighting AAV gene therapy pipeline led by 4D-150 for wet AMD, DMEPUBT·1 day ago, 10:28 AMFDMT-1.68%
4D Molecular Therapeutics CLO Scott Bizily disposes of common shares worth $39,567.5PUBT·Aug 17 at 04:34 PMFDMT-1.68%
4D Molecular Therapeutics grants 35,200 RSUs to five new hires under inducement award planPUBT·Aug 14 at 03:06 PMFDMT-1.68%
4D Molecular Therapeutics (NASDAQ:FDMT) Announces Quarterly Earnings ResultsMarket Beat·Aug 13 at 03:41 PMFDMT-1.68%
4D Molecular Therapeutics Q2 FY26 net loss widens to $72.94 million; revenue rises to $3.78 millionPUBT·Aug 13 at 03:12 PMFDMT-1.68%4578
Dimensional Fund Advisors LP Purchases 227,982 Shares of 4D Molecular Therapeutics, Inc. $FDMTMarket Beat·Aug 12 at 02:12 AMFDMT-1.68%8601
North American Morning Briefing: Stock Futures Edge Up as Investors Focus on Inflation Data -2-MorningStar·Aug 10 at 05:36 AMFDMT-1.68%B+2.87%
4D Molecular Therapeutics CEO David Kirn disposes of 12,415 shares worth $124,987PUBT·Aug 4 at 03:53 PMFDMT-1.68%
4D Molecular's One-Shot Eye Therapy Delivers Two-Year Winbenzinga_article·Jul 20 at 08:05 AMFDMT-1.68%
4D Molecular Therapeutics reports positive 2-year PRISM Phase 2b data, 78–87% reduction in injectionsTradingView·Jul 20 at 07:33 AMFDMT-1.68%
